ArticleFrontiers in oncology2020
NAP1L1: A Novel Human Colorectal Cancer Biomarker Derived From Animal Models of
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Targeting MYH9 represses USP14-mediated NAP1L1 deubiquitination and cell proliferation in glioma.Cancer cell international · 2023Article
- Review
- Role of Nucleolin in Endometrial Precancerous Hyperplasia and Carcinogenesis: Ex Vivo and In Silico Study.International journal of molecular sciences · 2022Article
- NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.BMC cancer · 2022Article
- Trametes robiniophila represses angiogenesis and tumor growth of lung cancer via strengthening let-7d-5p and targeting NAP1L1.Bioengineered · 2022Article
- NAP1L1 Functions as a Novel Prognostic Biomarker Associated With Macrophages and Promotes Tumor Progression by Influencing the Wnt/β-Catenin Pathway in Hepatocellular Carcinoma.Frontiers in genetics · 2022Article
- Article
- NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth.Cancer cell international · 2021Article
- NAP1L1 Functions as a Tumor PromoterFrontiers in cell and developmental biology · 2021Article
- NAP1L5 Promotes Nucleolar Hypertrophy and Is Required for Translation Activation During Cardiomyocyte Hypertrophy.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionColorectal cancer (CRC) is the second leading cause of cancer death worldwide and most deaths result from metastases. We have analyzed animal models in which MATERIALS AND
methodsWe initially compared the proteomic and transcriptomic profiles of the small intestinal epithelium of transgenic mice in which
results
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.